Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Non-Current Deffered Revenue: 2017-2021

  • Summit Therapeutics' Non-Current Deffered Revenue was N/A to $365,000 in Q2 2021 from the same period last year, while for Jun 2021 it was $365,000, marking a year-over-year change of. This contributed to the annual value of $569,000 for FY2020, which is 15.42% up from last year.
  • Per Summit Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $365,000 for Q2 2021, which was down 4.70% from $383,000 recorded in Q1 2021.
  • In the past 5 years, Summit Therapeutics' Non-Current Deffered Revenue ranged from a high of $29.3 million in Q1 2017 and a low of $365,000 during Q2 2021.
  • Its 3-year average for Non-Current Deffered Revenue is $598,378, with a median of $531,000 in 2019.
  • Data for Summit Therapeutics' Non-Current Deffered Revenue shows a peak YoY rose of 15.42% (in 2020) over the last 5 years.
  • Quarterly analysis of 4 years shows Summit Therapeutics' Non-Current Deffered Revenue stood at $29.3 million in 2017, then reached $493,000 in 2019, then increased by 15.42% to $569,000 in 2020, then reached $365,000 in 2021.
  • Its Non-Current Deffered Revenue stands at $365,000 for Q2 2021, versus $383,000 for Q1 2021 and $569,000 for Q4 2020.